

SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

[This is a group specific benefit](#)

Continuous Glucose Monitors (CGM), Subcutaneous Insulin Pumps & Combination Devices

Drug Requested: (Check below the CGM that applies, only **ONE** prior authorization form is required)

Formulary Preferred CGM's	
<input type="checkbox"/> FreeStyle Libre 14 Day System (Reader/Sensors)	<input type="checkbox"/> FreeStyle Libre 2 System (Reader/Sensors)
<input type="checkbox"/> Dexcom G6™ System (Receiver/Transmitter/Sensors)	<input type="checkbox"/> FreeStyle Libre 3 (Reader/Sensors)
<input type="checkbox"/> Dexcom G7™ System (Receiver/Transmitter/Sensors)	
Non-Formulary – Provider please note: Medical Exception is required for all Non-Formulary CGM requests via submission of the following form: <u>Pharmacy Medical Necessity Request Form</u>	
<input type="checkbox"/> Eversense® (Sensor/Transmitter)	<input type="checkbox"/> Guardian™ 3 (Transmitter/Sensors)
<input type="checkbox"/> Guardian™ 4 (Transmitter/Sensors)	

PROVIDER PLEASE NOTE: Only one prior authorization form is required to be submitted for the request of any formulary or non-formulary CGM. If approved, an authorization will be entered for corresponding CGM supplies (e.g., readers, sensors, transmitters).

FOR INSULIN PUMPS ONLY: Subcutaneous Insulin Pumps and Combination Devices are covered under the pharmacy benefit for VCUHS members only. All other Sentara Health Plans members will need to submit requests for coverage determination under the medical benefit.

(Continued on next page)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____
 Member Sentara #: _____ Date of Birth: _____
 Prescriber Name: _____
 Prescriber Signature: _____ Date: _____
 Office Contact Name: _____
 Phone Number: _____ Fax Number: _____
 NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____
 Dosing Schedule: _____ Length of Therapy: _____
 Diagnosis: _____ ICD Code, if applicable: _____
 Weight (if applicable): _____ Date weight obtained: _____

- Will the member be discontinuing a previously prescribed continuous glucose monitor (CGM) device and/or supplies if approved for the requested CGM?

Yes **OR** No

- If yes, please list the CGM device and/or supplies that will be discontinued and the CGM device and/or supplies that will be initiated upon approval along with the corresponding effective date.

Medication to be discontinued: _____ Effective date: _____

Medication to be initiated: _____ Effective date: _____

Quantity Limits:

<u>Dexcom</u>	<u>Freestyle</u>
<ul style="list-style-type: none"> • 1 receiver per lifetime • 3 sensors per 30 days • 1 transmitter per 90 days 	<ul style="list-style-type: none"> • 1 reader kit per lifetime • 2 sensors per 28 days

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ Continuous Glucose Monitors – Long Term Use

Length of Authorization: Indefinite

- ❑ Member requires Long-term CGM device indicated by **ALL** the following:
 - ❑ Diagnosis of **ONE** of the following:
 - ❑ Type 1 Diabetes Mellitus
 - ❑ Type 2 Diabetes Mellitus
 - ❑ Gestational Diabetes
 - ❑ Member requires a demanding insulin regimen of at least three or more insulin injections per day or current use of an insulin pump
 - ❑ Member or guardian consistently monitors blood glucose three or more times per day
 - ❑ Provider attests that the member is motivated and knowledgeable about use of CGMs, is adherent to diabetic treatment plan, and participates in ongoing education and support

❑ Continuous Glucose Monitors – Short Term Use

Length of Authorization: 1 month (30 days)

- ❑ Member requires Short-term CGM device indicated by **ALL** the following:
 - ❑ Diagnosis of **ONE** of the following:
 - ❑ Type 1 Diabetes Mellitus
 - ❑ Type 2 Diabetes Mellitus
 - ❑ Gestational Diabetes
 - ❑ Member must demonstrate at least **ONE** of the following:
 - ❑ Observed increase in blood glucose levels that takes place in the early morning (also known as The Dawn Phenomenon), known or suspected
 - ❑ Hypoglycemia unawareness (i.e., member does not have symptoms with hypoglycemia)
 - ❑ Nocturnal hypoglycemia, known or suspected
 - ❑ Postprandial hyperglycemia, known or suspected
 - ❑ Significant change to diabetes treatment regimen (e.g., initiation of insulin, change from multiple- dose insulin to insulin pump therapy)
 - ❑ Unexplained hyperglycemia
 - ❑ Member requires short term blood glucose monitoring (i.e., 7-14 days)

(Continued on next page)

❑ Subcutaneous Insulin Pumps and Combination Devices (Insulin Pump and CGM)

Group Specific Benefit: VCUHS Members Only

FOR INSULIN PUMPS ONLY: Subcutaneous Insulin Pumps and Combination Devices are covered under the pharmacy benefit for VCUHS members only. All other Sentara Health Plans members will need to submit requests for coverage determination under the medical benefit.

ALL the following criteria must be met:

- ❑ Provider is an endocrinologist
- ❑ Provider must submit **ALL** the following documentation:
 - ❑ Confirmation of Diagnosis
 - ❑ Two weeks of current blood glucose results obtained within the last 30 days
 - ❑ Glycosylated hemoglobin (HbA1c) lab result obtained within the last 6 months
- ❑ Member must demonstrate at least **ONE** of the following:
 - ❑ Observed increase in blood glucose levels that takes place in the early-morning (also known as The Dawn Phenomenon) known or suspected
 - ❑ Hypoglycemia unawareness (i.e. member does not have symptoms with hypoglycemia)
 - ❑ Metabolic control is inadequate, due to inconsistencies in insulin absorption with mixed insulin regimens
 - ❑ Member requires a demanding insulin regimen of at least three or more insulin injections per day
 - ❑ Optimal glycemic control has not been achieved as demonstrated by a recurrent, severe hypoglycemic event that may have resulted in hospitalization
- ❑ Provider attests that the member is motivated and knowledgeable about use of requested device, is adherent to diabetic treatment plan, and participates in ongoing education and support
- ❑ For members diagnosed with Gestational Diabetes, at least **ONE** of the following criteria must be met:
 - ❑ Member requires two or more insulin injections daily
 - ❑ Member has microalbuminuria >20 mcg/min
 - ❑ Member has proteinuria >120 mg/day
 - ❑ Member has a history of nephropathy
 - ❑ Member has a history of retinopathy

❑ Replacement Device

- ❑ Member has been previously approved for a CGM or insulin pump device
- ❑ At least **ONE** of the following problems have occurred which limits the use of the member's current CGM or insulin pump device
 - ❑ Abuse of equipment
 - ❑ Misuse of equipment
 - ❑ Reagent or instrument failure/defective devices

(Continued on next page)

- Defects in product design
- Product instability
- Failure to perform according to performance characterized in package insert
- Incorrect test results (falsely elevated or decreased glucose results) that cause or contributed to an incorrect patient diagnosis and/or treatment
- Unexplained quality control (QC) failures
- Any other device problems that may compromise patient health or safety
- Provider or member must submit documentation that the member's current CGM or insulin pump device is not under warranty, including the date of warranty expiration

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.